

# Karoline V Gleixner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/360327/publications.pdf>

Version: 2024-02-01

42  
papers

1,496  
citations

393982

19  
h-index

329751

37  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1963  
citing authors

#	ARTICLE	IF	CITATIONS
1	PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. <i>Blood</i> , 2006, 107, 752-759.	0.6	235
2	Hereditary $\beta$ -tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. <i>Blood</i> , 2021, 137, 238-247.	0.6	113
3	International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. <i>Lancet Haematology</i> , 2019, 6, e638-e649.	2.2	101
4	Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. <i>Nature Chemical Biology</i> , 2012, 8, 905-912.	3.9	96
5	Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. <i>Haematologica</i> , 2007, 92, 1451-1459.	1.7	92
6	Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1819-1822.	1.9	91
7	Polo-like Kinase 1 (Plk1) as a Novel Drug Target in Chronic Myeloid Leukemia: Overriding Imatinib Resistance with the Plk1 Inhibitor BI 2536. <i>Cancer Research</i> , 2010, 70, 1513-1523.	0.4	86
8	Emicizumab for the treatment of acquired hemophilia A. <i>Blood</i> , 2021, 137, 410-419.	0.6	83
9	KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. <i>Blood</i> , 2011, 118, 1885-1898.	0.6	64
10	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2976.	1.8	64
11	Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. <i>Experimental Hematology</i> , 2007, 35, 1510-1521.	0.2	50
12	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1927-1938.	2.7	47
13	Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4233.	1.8	44
14	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 81-87.	2.0	42
15	Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. <i>Haematologica</i> , 2013, 98, 1450-1457.	1.7	39
16	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1519-1529.	1.7	36
17	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 807-814.	1.0	33
18	The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. <i>Haematologica</i> , 2018, 103, 799-809.	1.7	30

#	ARTICLE	IF	CITATIONS
19	Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. <i>Journal of Clinical Apheresis</i> , 2017, 32, 224-234.	0.7	28
20	Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation. <i>Oncotarget</i> , 2016, 7, 46466-46481.	0.8	19
21	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. <i>Haematologica</i> , 2018, 103, 1760-1771.	1.7	18
22	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. <i>Frontiers in Veterinary Science</i> , 2021, 8, 755258.	0.9	16
23	CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML. <i>EBioMedicine</i> , 2019, 50, 111-121.	2.7	14
24	TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML. <i>Oncotarget</i> , 2017, 8, 23061-23072.	0.8	13
25	Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients $\geq 60$ years. <i>American Journal of Hematology</i> , 2017, 92, E567-E574.	2.0	9
26	Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2021, 35, 3176-3187.	3.3	8
27	Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib. <i>Blood</i> , 2007, 110, 1541-1541.	0.6	6
28	Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance. <i>Blood</i> , 2021, 138, 1481-1481.	0.6	6
29	A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. <i>Leukemia Research</i> , 2019, 78, 36-44.	0.4	3
30	The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest. <i>Blood</i> , 2018, 132, 1363-1363.	0.6	2
31	Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis. <i>Blood</i> , 2005, 106, 3518-3518.	0.6	2
32	Major response of PNH to an AML chemotherapy protocol. <i>Annals of Hematology</i> , 2018, 97, 1487-1488.	0.8	1
33	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. <i>American Journal of Hematology</i> , 2021, 96, 719-726.	2.0	1
34	Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 4223-4223.	0.6	1
35	Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107. <i>Blood</i> , 2005, 106, 3516-3516.	0.6	1
36	Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1). <i>Blood</i> , 2005, 106, 3521-3521.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.. Blood, 2006, 108, 1365-1365.	0.6	1
38	The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network. Memo - Magazine of European Medical Oncology, 2013, 6, 114-118.	0.3	0
39	The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.. Blood, 2007, 110, 3554-3554.	0.6	0
40	Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax <sup>®</sup> ) on Growth and Viability of Canine and Human Neoplastic Mast Cells. Blood, 2008, 112, 861-861.	0.6	0
41	BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells.. Blood, 2010, 116, 3382-3382.	0.6	0
42	Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56bright NK Cells in Acute Myeloid Leukemia. Blood, 2014, 124, 1422-1422.	0.6	0